PQRI Case Study (7): PackOut Remedies to Minimize Contamination and Exposure - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

PQRI Case Study (7): PackOut Remedies to Minimize Contamination and Exposure
The seventh in a series of eight case studies from the Product Quality Research Institute focuses on packout remedies.


Pharmaceutical Technology


Isolation, drying, milling (including micronizing), and packaging operations for nonsterile APIs should be performed using a combination of suitably designed rooms and/or containment technology. The primary goals are to protect operators from exposure via the containment of the API, to minimize the risk of contamination of the API and packaging materials from other compounds and foreign material, and to minimize the risk of contamination of other compounds from the API. When evaluating isolation/packout environments for the API, it is important to consider the risk factors for contamination and operator exposure. The steps required to address the risks will vary based on processing step, equipment design, building finishes and design, and whether the facility is multipurpose or dedicated. The use of cleanable/controlled rooms, for example, presents the least risk but the use of engineering and processing controls can facilitate the use of other types of environments for isolating and packaging API.

This case study on packout remedies for mitigating contamination and exposure is the seventh of eight in a series put together by the Product Quality Research Institute Manufacturing Technical Committee (PQRI-MTC) risk-management working group. The series is meant to advance the understanding and application of the International Conference on Harmonization (ICH) Q9 Quality Risk Management guideline by providing actual examples of risk-management assessments used by the bio/pharmaceutical industry. The introductory article and first case study, on defining design space, appeared in the July 2011 issue of Pharmaceutical Technology (1). Subsequent case studies in the series (8 in total) can be viewed online at http://PharmTech.com/pqristudies.

In the current case study, the manufacturer identifies contamination and occupational exposure risk factors for final isolation and packout of nonsterile APIs and uses quality risk management to evaluate the proposed alternatives to minimize these risks.

Risk question and risk assessment method

The risk question developed for the subject case study was: Are there effective room designs and/or containment technologies that may be utilized during packout operations at existing facilities without significant capital investment to minimize the potential for cross contamination and operator exposure?


Table I: Risk-evaluation levels.
In this case study, the risk factors are more qualitative than quantitative. Therefore, the risk methodology selected for the subject case study was: a decision table or modified hazard and operability (HAZOP) study.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
27%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
32%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology,
Click here